How protein modifications affect androgen receptor signaling in prostate cancer
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
This study is looking at how certain proteins affect the way the androgen receptor works in advanced prostate cancer, especially when the cancer stops responding to usual hormone treatments, and it hopes to find new ways to combine existing therapies with new treatments to help patients facing this challenge.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11059872 on NIH RePORTER |
What this research studies
This research investigates the role of protein arginine methylation in regulating androgen receptor (AR) signaling in advanced prostate cancer. It aims to understand how specific proteins, PRMT1 and PRMT5, influence AR activity, particularly in cases where prostate cancer becomes resistant to standard hormonal therapies. By using advanced techniques like CRISPR/Cas9, the study will explore potential new treatment strategies that combine inhibitors of these proteins with existing AR antagonists. This approach could lead to more effective therapies for patients with castration-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those whose cancer has become resistant to hormonal therapies.
Not a fit: Patients with early-stage prostate cancer or those not experiencing androgen resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for men with advanced prostate cancer.
How similar studies have performed: Other research has shown promise in targeting androgen receptor signaling and protein modifications, indicating that this approach could be a meaningful advancement in treatment.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Viswanathan, Srinivas Raghavan — Dana-Farber Cancer Inst
- Study coordinator: Viswanathan, Srinivas Raghavan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.